Physician profile
David Shavelle
NPI 1154315919
$39,418.35
in general payments reported to CMS, 2019-2025
21 companies · $9,058 in 2025
The $9,058 reported for 2025 was more than what 88% of Interventional Cardiology providers received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,497 · 2020: $3,658 · 2021: $313 · 2022: $322 · 2023: $3,057 · 2024: $22K · 2025: $9,058.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $30K · Food and Beverage: $2,009 · Travel and Lodging: $1,984.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $29,635.00 |
| Food and Beverage | $2,009.28 |
| Travel and Lodging | $1,984.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $22,537.57 | 2019-2025 | Cardiomems, Mitraclip, Coroflow |
| Edwards Lifesciences Corporation | $15,630.58 | 2024-2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Boston Scientific Corporation | $342.34 | 2019-2024 | Sentinel |
| Abiomed | $189.55 | 2021-2022 | |
| Penumbra, INC. | $165.74 | 2021-2023 | Indigo System |
| Medtronic, INC. | $100.24 | 2022 | |
| Angiodynamics, INC. | $76.02 | 2024 | Alphavac |
| Cardiva Medical, INC. | $75.56 | 2024-2025 | Savvywire, Cardiva Vascade 6/7f Vcs |
| Biotronik INC. | $58.14 | 2022 | |
| Impulse Dynamics (USA) INC. | $36.04 | 2025 | Optimizer |
| Glaxosmithkline, LLC. | $25.31 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $24.47 | 2021 | |
| Amgen INC. | $22.90 | 2023 | Repatha |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $22.57 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $21.27 | 2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scpharmaceuticals INC. | $21.18 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $20.69 | 2025 | Eliquis |
| Ge Healthcare | $18.50 | 2019 | |
| Alnylam Pharmaceuticals INC. | $15.08 | 2022 | |
| Kestra Medical Technology Services, INC. | $14.60 | 2025 | Assure Wcd |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Shavelle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.